Literature DB >> 11418513

Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy.

D Honeybourne1, D Banerjee, J Andrews, R Wise.   

Abstract

The concentrations of gatifloxacin achieved after a single 400 mg oral dose were measured in plasma, epithelial lining fluid (ELF), alveolar macrophages (AMs) and bronchial mucosa (BM) using a microbiological assay. Fourteen patients undergoing fibre-optic bronchoscopy were studied. Mean plasma, ELF, AMs and BM concentrations, respectively, at 2, 4 and 12 h were as follows: 2 h: 3.96 mg/L, 6.00 mg/L, 69.10 mg/L, 6.24 mg/kg; 4 h: 3.22 mg/L, 6.16 mg/L, 77.32 mg/L, 5.32 mg/kg; 12 h: 1.74 mg/L, 2.98 mg/L, 61.95 mg/L, 3.00 mg/kg. These concentrations exceed the MIC(90)s for common respiratory pathogens such as Streptococcus pneumoniae (0.5 mg/L), Haemophilus influenzae (0.013 mg/L), Moraxella catarrhalis (0.05 mg/L), Chlamydia pneumoniae (0.125 mg/L) and Mycoplasma pneumoniae (0.06 mg/L).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11418513     DOI: 10.1093/jac/48.1.63

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.

Authors:  Sungmin Kiem; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

Review 2.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

3.  Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic Bronchitis.

Authors:  M Solèr; H Lode; R Baldwin; J H A Levine; A J M Schreurs; J A van Noord; F P V Maesen; M Zehrer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

4.  Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum.

Authors:  Gary E Stein; Sharon Schooley; Kerin L Tyrrell; Diane M Citron; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

5.  Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.

Authors:  Wynand Smythe; Corinne S Merle; Roxana Rustomjee; Martin Gninafon; Mame Bocar Lo; Oumou Bah-Sow; Piero L Olliaro; Christian Lienhardt; John Horton; Peter Smith; Helen McIlleron; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

Review 6.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones.

Authors:  J Mensa; A Trilla
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

8.  Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.

Authors:  Bing Chen; Hao-Qiang Shi; Meihua Rose Feng; Xi-Han Wang; Xiao-Mei Cao; Wei-Min Cai
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.